Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Cao Website

Liang Cao, Ph.D.

Selected Publications

1)  Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, Khozin S, Chavez AL, Bergagnini I, Scepura B, Szabo E, Lee MJ, Trepel JB, Browne SK, Rosen LB, Yu Y, Steinberg SM, Chen HX, Riely GJ, Giaccone G.
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.
Lancet Oncol. 2014.
2)  Harouaka R, Kang Z, Zheng S, Cao L.
Circulating tumor cells: Advances in isolation and analysis, and challenges for clinical applications.
Pharmacol. Ther. 2013.
3)  Kang Z, Yu Y, Zhu YJ, Davis S, Walker R, Meltzer PS, Helman LJ, Cao L.
Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma.
Oncogene. 2013.
4)  Kang Z, Sun SY, Cao L.
Activating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma.
ISRN Oncol. 2012: 395952, 2012.
5)  Kalra N, Zhang J, Yu Y, Ho M, Merino M, Cao L, Hassan R.
Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell.
Int J Cancer. 131: 2143-52, 2012.
6)  Speranza G, Gutierrez ME, Kummar S, Strong JM, Parker RJ, Collins J, Yu Y, Cao L, Murgo AJ, Doroshow JH, Chen A.
Phase I study of the synthetic triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumors.
Cancer Chemother. Pharmacol. 69: 431-8, 2012.
7)  Kang Z, Chen J, Yu Y, Li B, Sun S, Zhang B, Cao L.
Drozitumab, a Human Antibody to Death Receptor 5, Has Potent Antitumor Activity against Rhabdomyosarcoma with the Expression of Caspase-8 Predictive of Response.
Clin. Cancer Res. 17: 3181-3192, 2011.
8)  Kelly RJ, Rajan A, Force J, Lopez-Chavez A, Keen C, Cao L, Yu Y, Choyke P, Turkbey B, Raffeld M, Xi L, Steinberg SM, Wright JJ, Kummar S, Gutierrez M, Giaccone G.
Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Sorafenib.
Clin. Cancer Res. 17: 1190-9, 2011.
9)  Kummar S, Gutierrez ME, Chen A, Turkbey IB, Allen D, Horneffer YR, Juwara L, Cao L, Yu Y, Kim YS, Trepel J, Chen H, Choyke P, Melillo G, Murgo AJ, Collins J, Doroshow JH.
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas.
Eur. J. Cancer. 47: 997-1005, 2011.
10)  Giaccone G, Rajan A, Berman A, Kelly RJ, Szabo E, Lopez-Chavez A, Trepel J, Lee MJ, Cao L, Espinoza-Delgado I, Spittler J, Loehrer PJ.
Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors.
J. Clin. Oncol. 29: 2052-9, 2011.
11)  Terzuoli E, Puppo M, Rapisarda A, Uranchimeg B, Cao L, Burger AM, Ziche M, Melillo G.
Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1alpha expression in an AhR-independent fashion.
Cancer Res. 70: 6837-48, 2010.
12)  Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, Azorsa DO, Yang F, Pineda M, Helman LJ, Meltzer PS.
Genome-Wide Identification of PAX3-FKHR Binding Sites in Rhabdomyosarcoma Reveals Candidate Target Genes Important for Development and Cancer.
Cancer Res. 70: 6497-508, 2010.
13)  Mayeenuddin LH, Yu Y, Kang Z, Helman LJ, Cao L.
Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-x(L).
Oncogene. 29: 6367-77, 2010.
14)  Zucali PA, Petrini I, Lorenzi E, Merino M, Cao L, Di Tommaso L, Lee HS, Incarbone M, Walter BA, Simonelli M, Roncalli M, Santoro A, Giaccone G.
Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas.
Cancer. 116: 4686-95, 2010.
15)  Paoloni MC, Mazcko C, Fox E, Fan T, Lana S, Kisseberth W, Vail DM, Nuckolls K, Osborne T, Yalkowsy S, Gustafson D, Yu Y, Cao L, Khanna C.
Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs.
PLoS ONE. 5: e11013, 2010.
16)  Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM, Wright JJ, Yu Y, Cao L, Steinberg SM, Aragon-Ching JB, Venitz J, Jones E, Chen CC, Figg WD.
A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
Clin. Cancer Res. 14: 209-14, 2008.
17)  Cao L, Yu Y, Darko I, Currier D, Mayeenuddin LH, Wan X, Khanna C, Helman LJ.
Addiction to elevated insulin-like growth factor i receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody.
Cancer Res. 68: 8039-48, 2008.
18)  Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC.
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
J. Clin. Oncol. 26: 3709-14, 2008.
19)  Chen H, Hutt-Fletcher L, Cao L, Hayward SD.
A positive autoregulatory loop of LMP1 expression and STAT activation in epithelial cells latently infected with Epstein-Barr virus.
J. Virol. 77: 4139-48, 2003.
20)  Chan CM, Woo PC, Leung AS, Lau SK, Che XY, Cao L, Yuen KY.
Detection of antibodies specific to an antigenic cell wall galactomannoprotein for serodiagnosis of Aspergillus fumigatus aspergillosis.
J. Clin. Microbiol. 40: 2041-5, 2002.
21)  Woo PC, Chan CM, Leung AS, Lau SK, Che XY, Wong SS, Cao L, Yuen KY.
Detection of cell wall galactomannoprotein Afmp1p in culture supernatants of Aspergillus fumigatus and in sera of aspergillosis patients.
J. Clin. Microbiol. 40: 4382-7, 2002.
22)  Jakt LM, Cao L, Cheah KS, Smith DK.
Assessing clusters and motifs from gene expression data.
Genome Res. 11: 112-23, 2001.
23)  Yuen KY, Chan CM, Chan KM, Woo PC, Che XY, Leung AS, Cao L.
Characterization of AFMP1: a novel target for serodiagnosis of aspergillosis.
J. Clin. Microbiol. 39: 3830-7, 2001.
24)  Wong SS, Wong KH, Hui WT, Lee SS, Lo JY, Cao L, Yuen KY.
Differences in clinical and laboratory diagnostic characteristics of penicilliosis marneffei in human immunodeficiency virus (HIV)- and non-HIV-infected patients.
J. Clin. Microbiol. 39: 4535-40, 2001.
25)  Xin B, He Z, Yang X, Chan CP, Ng MH, Cao L.
TRADD domain of Epstein-Barr virus transforming protein LMP1 is essential for inducing immortalization and suppressing senescence of primary rodent fibroblasts.
J. Virol. 75: 3010-5, 2001.
26)  Ng IO, Liang ZD, Cao L, Lee TK.
DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1.
Cancer Res. 60: 6581-4, 2000.
27)  Yang X, Sham JS, Ng MH, Tsao SW, Zhang D, Lowe SW, Cao L.
LMP1 of Epstein-Barr virus induces proliferation of primary mouse embryonic fibroblasts and cooperatively transforms the cells with a p16-insensitive CDK4 oncogene.
J. Virol. 74: 883-91, 2000.
28)  Yang X, He Z, Xin B, Cao L.
LMP1 of Epstein-Barr virus suppresses cellular senescence associated with the inhibition of p16INK4a expression.
Oncogene. 19: 2002-13, 2000.
29)  He Z, Xin B, Yang X, Chan C, Cao L.
Nuclear factor-kappaB activation is involved in LMP1-mediated transformation and tumorigenesis of rat-1 fibroblasts.
Cancer Res. 60: 1845-8, 2000.
30)  Cao L, Chan KM, Chen D, Vanittanakom N, Lee C, Chan CM, Sirisanthana T, Tsang DN, Yuen KY.
Detection of cell wall mannoprotein Mp1p in culture supernatants of Penicillium marneffei and in sera of penicilliosis patients.
J. Clin. Microbiol. 37: 981-6, 1999.
31)  Cao L, Chen DL, Lee C, Chan CM, Chan KM, Vanittanakom N, Tsang DN, Yuen KY.
Detection of specific antibodies to an antigenic mannoprotein for diagnosis of Penicillium marneffei penicilliosis.
J. Clin. Microbiol. 36: 3028-31, 1998.
32)  Cao L, Chan CM, Lee C, Wong SS, Yuen KY.
MP1 encodes an abundant and highly antigenic cell wall mannoprotein in the pathogenic fungus Penicillium marneffei.
Infect. Immun. 66: 966-73, 1998.
33)  Cheng RY, Yuen PW, Nicholls JM, Zheng Z, Wei W, Sham JS, Yang XH, Cao L, Huang DP, Tsao SW.
Telomerase activation in nasopharyngeal carcinomas.
Br. J. Cancer. 77: 456-60, 1998.
34)  Siau H, Yuen KY, Peiris JS, Wong SS, Ho PL, Cao L, Yam WC, Shortridge KF, Chau PY, Im SW, Ng MH.
Emerging pathogens: the Hong Kong experience.
Chin. Med. J. 110: 560-6, 1997.
35)  Storlazzi A, Xu L, Cao L, Kleckner N.
Crossover and noncrossover recombination during meiosis: timing and pathway relationships.
Proc. Natl. Acad. Sci. U.S.A. 92: 8512-6, 1995.
36)  Adams MD, Kerlavage AR, Fleischmann RD, Fuldner RA, Bult CJ, Lee NH, Kirkness EF, Weinstock KG, Gocayne JD, White O.
Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence.
Nature. 377: 3-174, 1995.
37)  Cao L, Faha B, Dembski M, Tsai LH, Harlow E, Dyson N.
Independent binding of the retinoblastoma protein and p107 to the transcription factor E2F.
Nature. 355: 176-9, 1992.
38)  Padmore R, Cao L, Kleckner N.
Temporal comparison of recombination and synaptonemal complex formation during meiosis in S. cerevisiae.
Cell. 66: 1239-56, 1991.
39)  Cao L, Alani E, Kleckner N.
A pathway for generation and processing of double-strand breaks during meiotic recombination in S. cerevisiae.
Cell. 61: 1089-101, 1990.
40)  Alani E, Cao L, Kleckner N.
A method for gene disruption that allows repeated use of URA3 selection in the construction of multiply disrupted yeast strains.
Genetics. 116: 541-5, 1987.
Click Here to View Collapsed Bibliography.

This page was last updated on 5/22/2014.